ReviewDrugs1993
Quinolones in the treatment of lower respiratory tract infections in adult patients.
Review in Drugs, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 9 citations in OpenAlex.
- Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.Antimicrobial agents and chemotherapy · 2000Article
- Review
- Review
- Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.Drugs & aging · 1994Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The potential role of quinolones is discussed on the basis of data obtained during the past 2 years from epidemiological studies, in vitro investigations, animal experiments and clinical trials. Although the newest compounds exhibit good activity against Streptococcus pneumoniae and intracellular pathogens in animal models, the role of quinolones as first line therapy in community-acquired pneumonia is still debatable and may be modified according to clinical presentation and the rate of resistance of pneumococci to beta-lactams and macrolides. Cost-utility and cost-benefit studies are required to delineate precisely the role of quinolones in the treatment of acute exacerbations of chronic bronchitis. In addition, promising results indicating a possible future for the clinical use of quinolones in the therapy of mycobacterial infections have been obtained.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.